C1 FUNCTION ANALYZED WITH NATURALLY-OCCURRING INHIBITORS
使用天然抑制剂分析 C1 功能
基本信息
- 批准号:3232415
- 负责人:
- 金额:$ 20.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1983
- 资助国家:美国
- 起止时间:1983-12-01 至 1997-06-30
- 项目状态:已结题
- 来源:
- 关键词:SDS polyacrylamide gel electrophoresis blocking antibody carbohydrate sequence complement complement inhibitors complement pathway gene expression glycosidases heparan sulfate high performance liquid chromatography human tissue laboratory mouse laboratory rabbit mass spectrometry monoclonal antibody posttranslational modifications protein biosynthesis protein purification protein sequence protein structure function
项目摘要
When immune complexes bind the C1q subcomponent of C1, the bound C1q has
two important activities: 1) providing a binding site for C1r2s2, the
catalytic unit of C1, which activates the rest of the complement cascade;
and 2) stimulating cells bearing the C1q receptor. The overall objectives
of this proposal are to identify and characterize the natural inhibitors of
C1, which are responsible for the specific and restricted functional
activity of C1 in vivo. In particular, we are focusing on two inhibitors,
Factor J and heparan sulfate, which are potentially able to control the
recycling of bound C1q as an activator of Clr2s2, and as a stimulus to
cells bearing C1q receptors.
Factor J was initially identified and isolated from human urine and serum
in the Principal Investigator's laboratory. It is a heavily glycosylated,
basic protein, comprised of 200,000, 18,000, and 5,900 subunits, which is
expressed on some circulating cells. Factor J binds to C1q and is a potent
non-competitive inhibitor of the assembly of macromolecular C1 from the C1q
and C1r2s2 subcomponents. It is structurally and functionally distinct
from other known inhibitors of C1. The protein sequence of Factor J will
be determined by Edman degradation or mass spectrometry using proteolytic
fragments of deglycosylated protein. By producing high titer polyclonal
and monoclonal antibodies it will be possible to define the functional and
antigenic domains of the protein, characterize the expression of Factor J
antigen in various tissues, and perform biosynthetic studies.
当免疫复合物结合C1的C1q亚组分时,结合的C1q具有
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANNE NICHOLSON-WELLER其他文献
ANNE NICHOLSON-WELLER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANNE NICHOLSON-WELLER', 18)}}的其他基金
CR1 (CD35) AS A CELLULAR RECEPTOR FOR CIQ
CR1 (CD35) 作为 CIQ 的细胞受体
- 批准号:
2887721 - 财政年份:1998
- 资助金额:
$ 20.16万 - 项目类别:
CRI (CD35) As a Cellular Receptor for CIq
CRI (CD35) 作为 CIq 的细胞受体
- 批准号:
6711776 - 财政年份:1998
- 资助金额:
$ 20.16万 - 项目类别:
CR1 (CD35) AS A CELLULAR RECEPTOR FOR CIQ
CR1 (CD35) 作为 CIQ 的细胞受体
- 批准号:
6170691 - 财政年份:1998
- 资助金额:
$ 20.16万 - 项目类别:
CR1 (CD35) AS A CELLULAR RECEPTOR FOR CIQ
CR1 (CD35) 作为 CIQ 的细胞受体
- 批准号:
6373824 - 财政年份:1998
- 资助金额:
$ 20.16万 - 项目类别:
CR1 (CD35) AS A CELLULAR RECEPTOR FOR CIQ
CR1 (CD35) 作为 CIQ 的细胞受体
- 批准号:
2607884 - 财政年份:1998
- 资助金额:
$ 20.16万 - 项目类别:
CRI (CD35) As a Cellular Receptor for CIq
CRI (CD35) 作为 CIq 的细胞受体
- 批准号:
6866409 - 财政年份:1998
- 资助金额:
$ 20.16万 - 项目类别:
CRI (CD35) As a Cellular Receptor for CIq
CRI (CD35) 作为 CIq 的细胞受体
- 批准号:
7191597 - 财政年份:1998
- 资助金额:
$ 20.16万 - 项目类别:
CRI (CD35) As a Cellular Receptor for CIq
CRI (CD35) 作为 CIq 的细胞受体
- 批准号:
6630106 - 财政年份:1998
- 资助金额:
$ 20.16万 - 项目类别:
CRI (CD35) As a Cellular Receptor for CIq
CRI (CD35) 作为 CIq 的细胞受体
- 批准号:
7019994 - 财政年份:1998
- 资助金额:
$ 20.16万 - 项目类别:
COMPLEMENT--PLASMA MEMBRANE FUNCTIONAL INTERACTIONS
补体--质膜功能相互作用
- 批准号:
6330018 - 财政年份:1989
- 资助金额:
$ 20.16万 - 项目类别:
相似海外基金
A Humanized Monoclonal FSH Blocking Antibody for Alzheimer's Disease
治疗阿尔茨海默病的人源化单克隆 FSH 阻断抗体
- 批准号:
10279706 - 财政年份:2021
- 资助金额:
$ 20.16万 - 项目类别:
A Humanized Monoclonal FSH Blocking Antibody for Alzheimer's Disease
治疗阿尔茨海默病的人源化单克隆 FSH 阻断抗体
- 批准号:
10693288 - 财政年份:2021
- 资助金额:
$ 20.16万 - 项目类别:
Study of suppressing effect by PAD4 catalytic cleft blocking antibody to rheumatoid arthritis and interstitial pneumonitis
PAD4催化裂隙阻断抗体对类风湿性关节炎和间质性肺炎抑制作用的研究
- 批准号:
17K09982 - 财政年份:2017
- 资助金额:
$ 20.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Characterization of a GPCR-blocking antibody for the treatment of breast cancer.
用于治疗乳腺癌的 GPCR 阻断抗体的表征。
- 批准号:
8199615 - 财政年份:2011
- 资助金额:
$ 20.16万 - 项目类别:
Regulation of the IL-31 function by the blocking antibody to IL-31 receptor
IL-31 受体阻断抗体对 IL-31 功能的调节
- 批准号:
22591230 - 财政年份:2010
- 资助金额:
$ 20.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The detection of blocking antibody against plasma thrombopoietin in subjects with childhood idiopathic thrombocytopenic purpura
儿童特发性血小板减少性紫癜患者血浆血小板生成素阻断抗体的检测
- 批准号:
13670842 - 财政年份:2001
- 资助金额:
$ 20.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




